This study evaluated whether the reduction in epileptiform activity after treatment with high-dose diazepam in continuous spikes and waves during sleep persists over time. PATIENTS: Patients aged 1 to 21 years with continuous spikes and waves during sleep who received high-dose nocturnal diazepam and who had electroencephalogram follow-up were included. Twenty-nine patients met the inclusion criteria and underwent a total of 48 highdose diazepam treatment cycles. RESULTS: An overnight reduction of the spike wave percentage of at least 25% (i.e., 75-50%) occurred in 29 cycles (20 patients), and persisted within 6 months in 16 of 29 cycles (12 patients), but returned to baseline in three of 29 cycles (three patients). An overnight reduction of at least 50% (i.e., 75-25%) occurred in 15 cycles (13 patients), and persisted within 6 months in eight of 15 cycles (eight patients), but returned to baseline in three cycles (three patients). Twenty of 29 cycles that responded in the short term had persistent response on follow-up. Thirteen cycles of treatment were associated with mild side effects that did not recur with repeated treatment cycles. CONCLUSIONS: Treatment with high-dose diazepam reduced epileptiform activity in continuous spikes and waves during sleep in the short term, and improvement persisted for several months in most cycles. Short-term response predicted persistence of this effect on subsequent follow-up.
Introduction
Interictal epileptiform activity can be sleep potentiated and tends to become more generalized during nonrapid eye movement sleep. 1, 2 The most dramatic sleep potentiation of epileptiform activity is observed during electrical status epilepticus in sleep. In electrical status epilepticus in sleep marked potentiation of epileptiform activity in the transition from wakefulness to sleep results in an electroencephalographic pattern of near-continuous spikes and waves that occupy a significant proportion of the nonrapid eye movement sleep electroencephalographic tracing. [3] [4] [5] Frequent and prolonged interictal epileptiform activity is thought to cause a disruption of normal cognitive processes. [6] [7] [8] [9] Patients with continuous spikes and waves during sleep present with electrical status epilepticus in sleep patterns on electroencephalogram in association with a severe and global regression on most aspects of development. 4, 5 Consequently, several authors assume that successfully treating the electrical status epilepticus in sleep patterns on the electroencephalogram may also improve the neurocognitive prognosis of patients with continuous spikes and waves during sleep, 5, [9] [10] [11] [12] [13] [14] [15] [16] [17] although this aspect remains to be proven. 6, 18 To date, there is a lack of detailed studies characterizing this assumed beneficial effect of reduction of epileptiform activity on cognition. A major limitation when studying this correlation is the scarce data on the influence of antiepileptic treatment on epileptiform activity. Short-term reduction of epileptiform activity following treatment with high-dose diazepam was described in several series. 11, [19] [20] [21] However, specific studies outlining follow-up of the interictal epileptiform activity after treatment are not available, and therefore it is still unclear whether reduction in epileptiform activity persists over time.
The aim of this study was to address this gap. This article presents a consecutive series of patients with continuous spikes and waves during sleep defined based on electroencephalographic assessment of the spike wave percentage and on regression or stagnation in at least two domains of development who underwent treatment with high-dose diazepam and had available long-term follow-up. The specific objectives were (1) to evaluate whether reduction of epileptiform activity persists over time and (2) to describe the reported clinical changes to this treatment.
Patients and Methods
This study was approved by the institutional review board of Boston Children's Hospital. This is a case series.
Patients were included during 8 consecutive years. Included patients were aged 1 to 21 years with the electrical status epilepticus in sleep pattern on electroencephalogram (!50% of spike waves during nonrapid eye movement sleep). They had received the high-dose nocturnal diazepam treatment protocol and had epileptiform activity evaluated the night before and after the initiation of high-dose diazepam treatment. The patients had at least one follow-up electroencephalogram that included sleep. Patients were excluded when they had a lack of information on the indication for high-dose diazepam treatment, or had treatment with high-dose diazepam protocol without the electrical status epilepticus in sleep pattern on electroencephalogram, or had no regression or stagnation associated with the electrical status epilepticus in sleep pattern, or had mild regression or stagnation in only one aspect of development that could not be differentiated from normal fluctuations in the natural course of their disease.
High-dose diazepam treatment protocol
A treatment cycle with the high-dose nocturnal diazepam treatment protocol consisted of oral administration of 1 mg/kg of diazepam (maximum of 40 mg) before sleep on the first night, 0.5 mg/kg (maximum of 20 mg) before sleep each night during the following month(s), and subsequent medication weaning to avoid withdrawal symptoms. The protocol used was based on a previously described rectal diazepam treatment protocol 19 and variants. 11, 20 Changes in the dose and duration of administration of diazepam were made based on the clinical response and treatment tolerability in each individual patient.
Electroencephalogram analysis
All patients underwent continuous overnight electroencephalographic monitoring to study the electroencephalogram pattern of electrical status epilepticus in sleep. Scalp electroencephalographic recordings were placed according to the 10-20 international system. Electroencephalographic recordings were continuously monitored throughout the day and night by dedicated electroencephalogram technologists. For the purposes of this study, a patient was considered to exhibit electrical status epilepticus in sleep in the electroencephalogram when the spike percentage during nonrapid eye movement sleep was 50% or more. The epileptiform activity was quantified using the first minutes of nonrapid eye movement sleep. For the purposes of quantification, focal and generalized discharges were considered equivalent. The percentage of epileptiform activity was calculated as the percentage of 1-second bins with at least one spike wave in them, as in the series by Aeby et al. 22 and reproduced by our group. 23 This was evaluated during the night prior to initiation of high-dose diazepam treatment, during the night after treatment initiation, and on the follow-up electroencephalograms with sleep.
Analysis of clinical data
Demographic and clinical variables were extracted by retrospective chart review, including age at occurrence of the main clinical events 23 and age at the use of high-dose diazepam treatment. Information was also collected on the different domains of development such as cognitive, motor, language or behavioral developmental delay, stagnation, or regression. Information on other comorbidities was also collected and included autistic spectrum disorders, attention-deficit/hyperactivity disorder, and learning and memory deficits. The assessment of development was based on the information recorded by the primary provider in the clinical charts. The use of concomitant antiepileptic treatments was also documented. Descriptive statistics were performed where appropriate and the clinical course was graphically documented for each patient.
We performed descriptive statistical analysis using SPSS 19 (SPSS Inc, Chicago, IL).
Results

Patients
This retrospective review identified 29 patients meeting inclusion criteria. All patients presented with the electrical status epilepticus in sleep pattern on electroencephalogram and had regression or stagnation in at least two domains of development, therefore they met continuous spikes and waves during sleep diagnosis and were treated with the high-dose diazepam protocol (Fig 1) .
Demographic characteristics and clinical features
Overall, 12 (41%) patients had abnormal development prior to regression or stagnation. Twenty-six (90%) patients were enrolled in special education at last follow-up. Details on the demographic data and clinical events are presented in Table 1 The treatment strategies in this patient population are presented in Fig 2 and Supplementary Fig 1. This overview demonstrates that polypharmacy is used more frequently than monotherapy for continuous spikes and waves during sleep and that treatment with high-dose diazepam frequently results in acute reduction of epileptiform activity that persists in time in most instances.
Response of epileptiform electroencephalogram activity to high-dose diazepam treatment
The 29 patients underwent a total of 48 cycles of treatment with high-dose diazepam. Fourteen patients underwent only one cycle of treatment, 11 patients underwent two cycles of treatment, and four patients underwent three cycles of treatment. The need for several treatment cycles in some patients derived from relapse over time, but not because of treatment failure. The median (P25-P75) duration of the treatment during the acute phase was 4 weeks (3.25-8 weeks) and the median (P25-P75) duration of the taper period was 4 weeks (4-8 weeks) ( Supplementary Fig 2) . An overnight reduction of at least 25% (i.e., 75-50%) occurred in 29 cycles (20 patients) and persisted within 6 months in 16 of 29 cycles (12 patients), while the spike wave percentage returned to baseline in three of 29 cycles (three patients). Within this 6-month follow-up period, the median (P25-P75) duration of follow-up was 13 weeks (6-20 weeks). Follow-up data within 6 months were not available for 10 cycles. An overnight reduction of at least 50% (i.e., 75-25%) occurred in 15 cycles (13 patients), persisted within 6 months in eight of 15 cycles (eight patients), and returned to baseline in three of 15 cycles (three patients). There was no information on the follow-up within 6 months for four cycles. Individual patient information on the clinical features, domains of development, and response to treatment can be found in Table 2 and Supplementary Table 1 .
Relationship between short-term and follow-up electroencephalographic responses
Of the 29 cycles (20 patients) that responded (at least 25% reduction in epileptiform activity) to treatment in the first 24 hours, 20 cycles (14 patients) had persistent response (at least 25% reduction in epileptiform activity as compared to pretreatment baseline) on follow-up, six cycles (six patients) did not have persistent responses on followup (returned to baseline), and three cycles (three patients) did not have follow-up. No response (<25% reduction in epileptiform activity) to treatment in the first 24 hours occurred in 19 cycles (17 patients). Of those, 12 cycles (10 patients) did not respond on subsequent follow-up, five cycles (five patients) responded (at least 25% reduction in epileptiform activity as compared to pretreatment baseline) on subsequent follow-up, and two cycles (two patients) did not have follow-up (Table 2) . Although the period of follow-up varied among different patients, there was a significant correlation between the absolute spike wave percentage 24 hours after treatment in relationship to the spike wave percentage at last follow-up (Spearman correlation coefficient of 0.332; P ¼ 0.03). However, the reduction in spike wave percentage after the first 24 hours of treatment (difference in spike wave percentage from baseline to 24 hours after treatment) did not correlate with the spike wave percentage reduction at last follow-up (difference in spike percentage from baseline to last follow-up), but there was a tendency toward a negative correlation that did not achieve statistical significance (Spearman correlation coefficient of À0.278; P ¼ 0.071).
Modification of the clinical features in response to high-dose diazepam treatment
Based on clinical assessment, most patients who presented with an improvement in epileptiform activity also had a concomitant improvement in developmental features ( Table 2 and Supplementary Table 1 ).
Adverse events
Side effects occurred in 13 cycles of treatment (13 patients) and included agitation (five cycles), sedation (three cycles), ataxia (three cycles), hallucinations (two cycles), and emotional lability (one cycle). In one treatment cycle, agitation and hallucinations appeared together. Adverse events were mild in most cases and led to shortening or interruption of the protocol in three cycles (6.25% of the cycles). After an adverse event during one treatment cycle, seven patients were treated with at least one other cycle of high-dose diazepam (at the same weight-adjusted doses as in the initial treatment). During this repeat treatment neither the previously noted side effects nor different adverse events were seen. Therefore, no adverse events occurred upon repeated treatment after a first adverse event (Table 2 and Supplementary Table 1 ).
Discussion
This series shows that high-dose diazepam treatment reduces epileptiform activity in the short term for most patients with continuous spikes and waves during sleep, and this reduction lasts for several months in a majority of patients.
Note on the use of terminology
The use of terminology in the literature on electrical status epilepticus in sleep and continuous spikes and waves during sleep is heterogeneous. 24 For the purposes of this study, the term electrical status epilepticus in sleep was used to refer to the electroencephalographic pattern only and the term continuous spikes and waves during sleep was used to refer to the clinical syndrome of severe cognitive regression that occurs with the electroencephalographic pattern. 4 A subgroup of patients with developmental regression or stagnation in at least two different aspects of development (continuous spikes and waves during sleep) was selected in order to have information on the evolution of the developmental features.
Demographic characteristics and clinical features
Subgroups of this patient population have been already described in previous studies 21, 23, 25, 26 and presented with similar demographic findings to those in series from other groups. 10, 11, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] We noticed a delay of around 1 year between neurocognitive regression or stagnation that occurred around age 5 years and recognition of the electrical status epilepticus in sleep pattern that clustered around age 6 years. This difference suggests that patients with epilepsy who regress should have an electroencephalogram with sleep to evaluate for the possibility of electrical status epilepticus in sleep.
Treatment options in continuous spikes and waves during sleep
Treatment strategies in continuous spikes and waves during sleep are mostly based on case reports and small uncontrolled series. 13, 38 The comparison of therapeutic strategies used in different studies is challenging because of heterogeneous patient populations, different drug doses, frequent polytherapy, variable durations of treatment, different measures of outcome, and naturally occurring fluctuations in severity over time. Therefore, available studies in the literature do not allow detailed evidence-based comparisons among different treatment options. However, this study provided information on results that can be similar to those in other series. In a study of 44 patients with electrical status epilepticus in sleep and different clinical presentations, corticosteroids normalized the electroencephalogram in 48% of patients. 39 In a series of 18 patients with electrical status epilepticus in sleep and different clinical presentations, levetiracetam reduced the epileptiform activity, although the use of a different method for quantification prevented direct comparison with other results. 40 Neuropsychological outcomes are generally more heterogeneously described and, therefore, more difficult to compare. 39, 41 One treatment approach that has been reproduced at several centers includes the use of highdose benzodiazepines for treatment of the epileptiform activity.
11,19-21 The short-term decrease in epileptiform activity following treatment with high-dose benzodiazepines is well documented both qualitatively 11, 19, 20 and quantitatively. 21 However, the response of epileptiform activity to treatment in these patients has not been followed up over a longer time period. This series shows that those patients whose epileptiform activity responds to high-dose diazepam in the short term have a persistent reduction for several months.
Modification of clinical features following treatment of the epileptiform activity
Improvement of interictal epileptiform activity in continuous spikes and waves during sleep may also be accompanied by improvement in the clinical features. 7, 9, 42 However, published data are contradictory, 6 and the correlation of interictal epileptiform activity with cognitive features is not always consistent. 18, 20, 22, 43 This series 
Relationship between short-term and follow-up responses
Of 29 cycles that responded acutely, 20 (69%) cycles had a persistent response on follow-up. Of 19 cycles that did not respond acutely, 12 (63%) did not respond on follow-up. Therefore, the response to high-dose diazepam during the first night was suggestive of the response on follow-up (Table 2 and Supplementary Table 1 ). Based on these data, it is reasonable to recommend continuation of treatment in patients who respond during the first night because their probability of a relatively prolonged response is high. In those patients who do not respond during the first night, continuation of treatment should be based on best clinical judgment and, even if chances of success are low, a short trial to assess delayed response may be reasonable if clinically indicated.
Adverse events
In concordance with previous studies, adverse events were relatively infrequent, mild, and led to discontinuation of the treatment in a minority of individuals. 11, [19] [20] [21] Interestingly, this series confirms and expands on these findings by showing that in 54% of patients who presented with an adverse event during the first cycle did not have this side effect during subsequent diazepam treatment trials.
Strengths and weaknesses
Data need to be interpreted in the clinical context of the data acquisition. The decision to exclude patients with mild regression or stagnation in only one developmental domain may have led to selection of a subpopulation of patients with a more severe condition. However, this criterion was necessary to evaluate the clinical response to treatment and to exclude patients in whom normal fluctuations of their baseline condition may be confounded with regression or stagnation.
The approach in this study is limited in that it relies on the quantification of epileptiform activity and evaluation of clinical response as recorded in the clinical records. The intervals and timeline of follow-up were different for every patient, which jeopardized comparability. Because of the heterogeneous intervals of electroencephalogram assessment, the duration of the response cannot be summarized in a consistent way, but only be described for every individual patient.
Ideally, patients treated with high-dose diazepam should be compared with similar patients who did not undergo this treatment approach. However, the heterogeneity in the patient population and the natural fluctuations of the disease make this approach difficult. This study compared the epileptiform activity before and after treatment in each patient.
Only a prospective approach with standardized neuropsychological evaluation and standardized evaluation of epileptiform activity before and after treatment will conclusively answer the question of whether treatment of interictal epileptiform activity is associated with improvement in neurocognitive features. However, this retrospective series suggests that the evaluation of the response of epileptiform activity and neurocognitive function to high-dose benzodiazepine treatment is worth studying prospectively. figure. (The information in the entire patient population can be found in Supplementary Fig 1. 
Conclusion
This series shows that treatment with high-dose diazepam for continuous spikes and waves during sleep reduces epileptiform activity in the short term. This reduction persists for several months in most patients, and the presence of acute response correlates with persistence of this effect on subsequent follow-up. This series also suggests safety with mild adverse events that led to discontinuation in a minority of patients and did not recur with repeated high-dose diazepam administration cycles. 
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